Join us in exploring a new era in cellular therapy

At Rubius Therapeutics®, our vision is to bring potentially life‑changing cellular therapies to people living with cancer. We call these potential medicines Red Cell Therapeutics™.

Learn About
Red Cell Therapeutics™
Find
a Clinical Trial

Open Clinical Studies

Solid Tumors - RTX-240

Rubius Therapeutics is enrolling adults with relapsed/refractory or locally advanced solid tumor cancers into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. There are two Phase 1 arms enrolling adult patients with advanced solid tumor cancers – one to evaluate RTX-240 as monotherapy and the other to evaluate RTX-240 in combination with KEYTRUDA® (pembrolizumab)1. Refractory refers to patients who have received treatment, but the disease does not go into remission. Some patients experience remission and then a return of the disease, which is referred to as relapsed.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL


Solid Tumors - RTX-224

Rubius Therapeutics is enrolling adults with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, urothelial (bladder) cancer, head and neck cancer and triple-negative breast cancer, into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-224. Refractory refers to patients who have received treatment, but the disease does not go into remission. Some patients experience remission and then a return of the disease, which is referred to as relapsed.

LEARN MORE ABOUT THE RTX-224 CLINICAL TRIAL


Watch a video about Red Cell Therapeutics™️

Learn More about Red Cell Therapeutics

References:

  1. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


Thank you

We will contact you about your submission